GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) | ENROLLING NOW
If so, you should be aware of the opportunity to participate in the GESTALT Clinical Trial.
This clinical trial investigates how starting radiation immediately after brain tumor removal surgery can improve outcomes. All participants receive immediate radiation treatment with FDA-cleared, safe and effective GammaTile® Surgically Targeted Radiation Therapy (STaRT), followed by the Stupp protocol standard of care.1–3
Enrolling now at up to 15 hospitals across the country
For more information contact a participating hospital.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, yet effective treatment remains a challenge.4 The Stupp protocol standard of care for GBMs typically follows brain tumor removal surgery and includes external beam radiation therapy (EBRT) and oral chemotherapy with Temodar®, also called temozolomide or TMZ.1,4
A disadvantage of the Stupp protocol is that patients must wait for their surgical wounds to heal before they can start EBRT. Radiation treatment destroys cancer cells, shrinks tumors, and helps to prevent tumor regrowth.5 Since it typically takes 3- to 8-weeks to start EBRT, remaining tumor cells have the chance to repopulate.6,7 In fact, tumors regrow near the original area in up to 70% of patients while they are waiting for EBRT, lowering their chances of survival.1,8–11
Studies show that earlier radiation treatment may be more effective than later treatment.6,7 That’s why the GESTALT Clinical Trial starts GammaTile Therapy immediately at the completion of brain tumor removal surgery and follows with the Stupp protocol. The GESTALT Clinical Trial will provide more information on how starting radiation immediately, instead of waiting, can improve outcomes. This approach, when combined with EBRT and chemotherapy, has improved outcomes in patients with recurrent GBM and may offer the same benefit for newly diagnosed patients.12,13
As a GESTALT Clinical Trial participant, you will receive GammaTile for an immediate head STaRT against tumor regrowth. At the completion of your brain tumor surgery, the neurosurgeon will place the GammaTiles in the area that the tumor is most likely to return.2,3 Subsequently, you will receive the Stupp protocol standard of care treatment (consisting of 4 weekly cycles of EBRT + TMZ). The total radiation administered in this clinical trial is within standard radiation treatment levels.
The GESTALT Clinical Team will closely monitor your care. And you’ll be making a valuable contribution to future patients, helping to provide more information about how starting radiation immediately, instead of waiting, can improve outcomes.
References:
The GESTALT Trial is sponsored by GT Medical Technologies, Inc., the makers of GammaTile®. Please discuss the risks and benefits of participating in this clinical trial with your care team.
Indication: GammaTile is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
Safety Information: The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile should not be used for patients with a known history of hypersensitivity to bovine-derived materials.
GESTALT CLINICAL TRIAL for PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs)
©2022 GT Medical Technologies, Inc. I All rights reserved I GammaTile is a registered trademark of GT Medical Technologies, Inc.